IGES

What IGES does

IGES is a Berlin-based, privately-held health systems research and consulting firm founded in 1980 by scientists from the Technical University of Berlin. The group operates two principal businesses: IGES Institut, which delivers independent evidence-based research, evaluations, and expert opinions to German federal and state ministries, statutory and private health insurers, hospitals, and physician organizations; and IGES Pharma, which provides strategic market access consulting — HTA dossier preparation, pricing and reimbursement, real-world evidence generation, health economic modelling, biostatistics, and an in-house CRO — to pharmaceutical and MedTech manufacturers. Since 2022, IGES has executed an aggressive European expansion, establishing wholly-owned subsidiaries in the UK, France, Italy, and Spain, and acquiring a majority stake in Swedish MedTech access specialist Synergus RWE in 2023, bringing its operating footprint to eight European countries.

The firm's technical platform rests on four decades of statutory health insurer routine data (Routinedaten), accompanied access to the FDZ Gesundheit Research Data Centre covering approximately 73 million insured persons, and an interdisciplinary team of more than 200 experts spanning health economics, medicine, statistics, mathematics, and pharmacy. The group is organized into three divisions — Health Systems, Pharma, and MedTech — and since 2025 has been part of the athagoras Gruppe, a multi-firm platform combining Market Access, Regulatory Affairs, Pharmacovigilance, Real World Data, and IT services for the European health innovation market.

IGES generates revenue through commissioned research studies, expert opinions, evaluations, and consulting engagements delivered to institutional clients on a project-contract basis, typically multi-month engagements. The go-to-market is sales-led and direct: the firm engages ministry officials, health insurer executives, pharma market access teams, and MedTech manufacturers through account-based business development, often via public tender or direct commission, with thought-leadership amplified through industry congresses (BIO, ISPOR, ESMO) and publications such as the annual Reimbursement and Pricing of Pharmaceuticals in Europe guide.

Name

IGES

Legal name

IGES Institut GmbH

Website

https://iges.com

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

11–50 employees

Short description

IGES is a Berlin-based independent health systems research and consulting firm serving European government ministries, health insurers, pharmaceutical and MedTech manufacturers with evidence-based research, HTA, pricing and reimbursement, and real-world evidence services across eight countries.

Ownership category

akta.pro rank

Product category

Healthcare Research & Consulting

NAICS

Management Consulting Services (54161)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN)

akta.pro secondary industries

Health Economics & Outcomes Research (HEOR) (HLAIAKAB), Competitive Intelligence & Benchmarking (BPAHALAB)

Keywords

• Health system research
• Pharmaceutical market access
• Health technology assessment
• Real world evidence
• Healthcare consulting

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. Research and Consulting Services: IGES generates revenue through commissioned research studies, expert opinions (Gutachten), evaluations, publications, and consulting engagements for government bodies, health insurers, healthcare providers, and life sciences companies. Projects are billed on a contract basis, typically multi-month engagements.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

IGES is an independent research and consulting firm that delivers evidence-based health system research, expert opinions (Gutachten), health economic analyses, HTA dossier preparation, pricing and reimbursement strategy, and real-world evidence generation. It serves government ministries, statutory and private health insurers, hospitals, physician organizations, pharmaceutical and biotech companies, and medical device manufacturers across European markets, supporting the full pharmaceutical lifecycle from pivotal trial planning through post-launch lifecycle management. The company is organized into the IGES Institut (health systems research) and IGES Pharma division (market access consulting), with a pan-European subsidiary network in eight countries.

Product overview

IGES is a healthcare research and consulting company organized as IGES Group, with the core IGES Institut providing independent health systems research and the IGES Pharma division offering market access consulting for pharmaceutical companies. The product portfolio includes a range of specialized service capabilities (Biostatistics, Strategy, Stakeholder Engagement, Real World Evidence, Pricing & Reimbursement, HTA, Health Economic Modelling, Health Services Research) organized around solutions (Market Access Strategy, European Launch Management, Evidence Generation, EU-HTA). The group has expanded through acquisitions (Synergus RWE) and subsidiaries across Europe (France, Italy, Spain, UK) to provide localized consulting services. IGES Pharma operates as a service-based consulting practice rather than a software product platform.

Differentiator

Problem solved

Functional benefit

Products and services

• IGES Pharma — Market Access Consulting Division A division of IGES Group providing tailored market access solutions for pharmaceutical companies, from strategy development to full-service product launches across key European markets, including HTA, pricing, reimbursement, real-world evidence, and health economic modelling.
• European Launch Management Comprehensive market access support for launching products into key European markets, covering strategic planning, launch sequencing, data analysis, HTA submissions, KOL management, and pricing & reimbursement negotiations.
• EU-HTA Solution Navigation of the harmonized European HTA framework including pivotal evidence planning, EMA authorization support, Joint Clinical Assessment dossier preparation, and national pricing & reimbursement decision support.
• Evidence Generation Solution Real-world evidence collection services to enrich HTA applications, from study conceptualization through site recruitment, data collection, biostatistical analysis, to result presentation and HTA submission.
• Real World Evidence Services RWE generation including feasibility assessment, study conceptualization, clinical registry studies, chart reviews, non-interventional studies, and RWE submissions for HTA, supported by an in-house CRO.
• Health Technology Assessment (HTA) Services Complete HTA submissions including EU HTA dossier submissions, PICO scoping, gap analysis, agency consultations, pathway optimization, written statements, and oral hearing preparation for AMNOG procedure.
• Pricing & Reimbursement Services Pricing strategy and prognosis, price referencing and launch sequencing, price negotiations, pay-for-outcome models, managed entry agreements, strategic payer contracting, early access programs, hospital reimbursement, and internal reference pricing services.
• Health Services Research Services
• IGES Institut — Health System Research and Consulting Independent health system research, expert opinions, evaluations, health policy analyses, routine data analysis, care structure planning, and strategic consulting for government ministries, health insurers, hospitals, and other healthcare stakeholders in Germany.
• IMC clinicon — Hospital Consulting Consulting and services institute specialised in hospitals, offering benchmarking, analyses, and strategic consulting in the inpatient sector for hospital groups and medical care centres.
• Synergus RWE — MedTech Market Access (Acquired) MedTech market access specialist providing real-world evidence services using Scandinavian medical registries for evidence generation for medical devices, diagnostics, and digital health applications across Europe. Founded by Mattias Kyhlstedt, headquartered in Stockholm.
• Reimbursement and Pricing of Pharmaceuticals in Europe Guide Annual publication (now in eighth edition, 2026) providing a comprehensive guide to reimbursement and pricing systems across EU countries, including EU-HTA procedures, used as a reference resource for life sciences market access teams.

Quantifiable outcome

• Over 4,000 research and consulting projects completed since 1980
• +1 more outcomes

Named customers9 records

Segments6 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• CNHDRC (China National Health Development Research Center)minorStrategic or Co-development Partner · 1 May 2026The IGES Institut and the Chinese National Health Development Research Center (CNHDRC), an institution directly subordinate to the National Health Commission (NHC) of the People's Republic of China, signed a cooperation declaration of intent. The CNHDRC serves as the national competence centre for healthcare policy and economic research and advises on the development and evaluation of health reforms in China.
• IGES Pharma SpaincoreChannel Partner/ Reseller/ Distributor · 1 March 2025IGES Group opened a branch in Barcelona, Spain, providing strategic and market access consulting services for developers and manufacturers of pharmaceuticals with a focus on the Spanish market and Portugal. Chus Castillo Gutierrez serves as General Manager.
• IGES Italy Pharma ConsultingcoreChannel Partner/ Reseller/ Distributor · 1 January 2025IGES Group established a new subsidiary in Milan, Italy, offering strategic and market access consulting services for pharmaceutical developers and manufacturers targeting the Italian market. Dr Ilda Theka serves as Managing Director.
• athagoras GruppecoreOthers · 1 January 2025Since 2025, IGES Institut and IGES GmbH are part of the athagoras Gruppe, which unites further companies from the field of healthcare provision and health technologies with a focus on Market Access, Regulatory Affairs, Pharmacovigilance, Real World Data, and IT. The goal is to become a leading tech-driven European specialist service provider for health systems and for the clinical and commercial development of health innovations.
• IGES France Pharma ConsultingcoreChannel Partner/ Reseller/ Distributor · 11 October 2023A new subsidiary established by IGES Group to provide strategic and health economics consulting services for developers and manufacturers of medicinal products seeking to place products on the French and European markets. Pierre Moïse serves as operational director. France is the second-largest pharmaceutical market in Europe.
• Synergus RWEcoreStrategic or Co-development Partner · 5 July 2023IGES acquired a majority stake in Synergus RWE, a Swedish medtech market access specialist. Synergus RWE specialises in the design and execution of market access strategies for medical devices, diagnostics, and digital health applications in Europe, providing expertise in accessing and using medical registries in Northern Europe to generate real-world evidence (RWE). Synergus founder Mattias Kyhlstedt continues as CEO from Stockholm.
• IGES UK Pharma ConsultingcoreChannel Partner/ Reseller/ Distributor · 1 January 2022IGES Group established a UK subsidiary to provide parallel market access and consulting services for the United Kingdom. Santoke Naal serves as Managing Director.
• HealthEcon AG (Basel)coreStrategic or Co-development PartnerHealthEcon AG, based in Basel, Switzerland, is an affiliate of IGES providing market access services for Germany and Switzerland. It extends IGES's perspective on international price referencing and launch planning, particularly with regard to Switzerland as an independent yet strategically connected market.
• IMC cliniconminorStrategic or Co-development PartnerIMC clinicon is a consulting and services institute specialised in hospitals, offering benchmarking, analyses, and strategic consulting in the inpatient sector. It is a subsidiary of the IGES Group (based in Berlin) providing data-based expertise for hospitals.
• Auditorium FriedrichstraßeminorStrategic or Co-development PartnerThe Auditorium Friedrichstraße in Berlin serves as IGES's in-house conference and event centre, providing space for scientific events and hosting IGES clients and numerous other institutions.

Scale indicators9 records

Recent moves12 records

Expansion highlights6 records

Broad incumbents

• IQVIA: Global leader in life sciences commercial and clinical services with extensive European market access and HTA consulting. IGES France's operating director was recruited from IQVIA Consulting Services, directly evidencing head-to-head talent and capability competition with IGES.
• ICON plc: Major global CRO with dedicated market access and real-world evidence capabilities through its PRA Health Sciences and Symphony Health businesses. Competes with IGES's in-house CRO and biostatistics practice for late-phase RWE and HTA submission work.
• Parexel International: Large global CRO and biopharmaceutical services provider with substantial European market access and HTA consulting practices. Competes with IGES Pharma for AMNOG submissions, pricing negotiations, and pan-European launch support.
• Simon-Kucher & Partners: Global consulting firm with a dedicated Life Sciences practice covering pricing, reimbursement, and market access strategy. Competes directly with IGES Pharma's Pricing & Reimbursement capability for launch sequencing and payer negotiation engagements.

Direct peers

• Alira Health: European and US-based healthcare and life sciences consulting firm focused on market access, RWE, and product development. IGES Italy and Iberia Managing Directors were hired from Alira Health, evidencing it as a direct competitor for pan-European pharma market access engagements.
• Charles River Associates (CRA): Global consulting firm with a dedicated Life Sciences practice providing HTA, pricing & reimbursement, health economics, and market access services across Europe and the US; directly competes with IGES Pharma for multi-jurisdictional evidence and access engagements.
• The Analysis Group: Private economics and financial consulting firm with a large Health Care practice providing HEOR, biostatistics, and real-world evidence services to pharma and MedTech clients. Competes with IGES's Health Economic Modelling and RWE practices.
• WIG2 (Wissenschaftliches Institut für Gesundheitsökonomie und Gesundheitssystemforschung): Leipzig-based German health economics and health systems research institute. Direct domestic peer to IGES Institut in statutory health insurance routine data analysis, contribution rate studies, and healthcare policy research.

Emerging players

• Ingress-Health: European health economics and market access consultancy offering HTA, RWE, and pricing & reimbursement services. Niche European specialist competing with IGES Pharma for AMNOG and other EU HTA submission work.

Others

• Bain & Company (Healthcare practice): Global management consultancy with a substantial healthcare and life sciences practice advising pharma and biotech on market access, launch strategy, and commercial excellence. Adjacent competitor for top-tier strategic consulting engagements that overlap with IGES's higher-end advisory work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aim-iges

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IGES